 BetterLife Pharma Inc revealed that a pre-clinical study of its interferon AP-003 candidate to tackle the Delta variant of coronavirus COVID-19 had started at the ImPaKT Facility at Western University in Ontario. The study is being carried out in the lab of Dr Stephen Barr and his team in the department of Microbiology and Immunology at the Canadian university. 